| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | Lymphangiogenesis inhibitors for cancer and for graft survival | US15389509 | 2016-12-23 | US20170202915A1 | 2017-07-20 | Noorjahan Panjwani; Wei-Sheng Chen |
| Compositions and methods are provided for treating and/or preventing lymphangiogenesis in a subject by using an inhibitor of a galectin-8 protein in an amount effective to inhibit or to modulate an activity of the galectin-8 protein or a portion thereof sufficient to inhibit the lymphangiogenesis associated with cancer, corneal injury, dry eye disease, inflammation, lymphedema, organ rejection or graft rejection. | ||||||
| 2 | Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer | US13836414 | 2013-03-15 | US08927516B2 | 2015-01-06 | Alfonso Bellacosa; Timothy Yen; Neil Beeharry; Mitchell Smith |
| The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells. | ||||||
| 3 | COMBINATION OF DNA REPAIR INHIBITION WITH BENDAMUSTINE OR GEMCITABINE IN THE TREATMENT OF CANCER | US13836414 | 2013-03-15 | US20130303588A1 | 2013-11-14 | Alfonso Bellacosa; Timothy Yen; Neil Beeharry; Mitchell Smith |
| The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells. | ||||||
| 4 | COMBINATION OF DNA REPAIR INHIBITION WITH BENDAMUSTINE OR GEMCITABINE IN THE TREATMENT OF CANCER | US14540428 | 2014-11-13 | US20150164934A1 | 2015-06-18 | ALFONSO BELLACOSA; TIMOTHY YEN; NEIL BEEHARRY; MITCHELL SMITH; ROSSELLA TRICARICO; VIKRAM BHATTACHARJEE; PIETRO MANCUSO |
| The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells. | ||||||
| 5 | LYMPHANGIOGENESIS INHIBITORS FOR CANCER AND FOR GRAFT SURVIVAL | PCT/US2015037641 | 2015-06-25 | WO2015200601A3 | 2016-02-18 | PANJWANI NOORJAHAN; CHEN WEI-SHENG |
| Compositions and methods are provided for treating and/or preventing lymphangiogenesis in a subject by using an inhibitor of a galectin-8 protein in an amount effective to inhibit or to modulate an activity of the galectin-8 protein or a portion thereof sufficient to inhibit the lymphangiogenesis associated with cancer, corneal injury, dry eye disease, inflammation, lymphedema, organ rejection or graft rejection. | ||||||
QQ群二维码
意见反馈
意见反馈